Overview

Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fenix Innovation Group
Collaborators:
Monash Health
Neurotech International